日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial

在冈比亚开展的麻疹和风疹疫苗微针贴片研究:一项 1/2 期、双盲、双模拟、随机、阳性对照、年龄递减试验

Adigweme, Ikechukwu; Yisa, Mohammed; Ooko, Michael; Akpalu, Edem; Bruce, Andrew; Donkor, Simon; Jarju, Lamin B; Danso, Baba; Mendy, Anthony; Jeffries, David; Segonds-Pichon, Anne; Njie, Abdoulie; Crooke, Stephen; El-Badry, Elina; Johnstone, Hilary; Royals, Michael; Goodson, James L; Prausnitz, Mark R; McAllister, Devin V; Rota, Paul A; Henry, Sebastien; Clarke, Ed

A Nucleic Acid-Based Orthopoxvirus Vaccine Targeting the Vaccinia Virus L1, A27, B5, and A33 Proteins Protects Rabbits against Lethal Rabbitpox Virus Aerosol Challenge

一种靶向痘苗病毒L1、A27、B5和A33蛋白的核酸疫苗可保护兔子免受致命性兔痘病毒气溶胶攻击

Mucker, Eric M; Golden, Joseph W; Hammerbeck, Christopher D; Kishimori, Jennifer M; Royals, Michael; Joselyn, Mathew D; Ballantyne, John; Nalca, Aysegul; Hooper, Jay W

Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation

本研究方案为一项 1/2 期、单中心、双盲、双模拟、随机、阳性对照、年龄递减试验,旨在评估在冈比亚健康成人(18 至 40 岁)、已接种麻疹和风疹疫苗的幼儿(15 至 18 个月)以及未接种过麻疹和风疹疫苗的婴儿(9 至 10 个月)中,通过微针贴片递送的麻疹和风疹疫苗的安全性、耐受性和免疫原性。[麻疹和风疹疫苗微针贴片 1/2 期年龄递减试验]

Adigweme, Ikechukwu; Akpalu, Edem; Yisa, Mohammed; Donkor, Simon; Jarju, Lamin B; Danso, Baba; Mendy, Anthony; Jeffries, David; Njie, Abdoulie; Bruce, Andrew; Royals, Michael; Goodson, James L; Prausnitz, Mark R; McAllister, Devin; Rota, Paul A; Henry, Sebastien; Clarke, Ed

The Immunogenicity of Fractional Intradermal Doses of the Inactivated Poliovirus Vaccine Is Associated With the Size of the Intradermal Fluid Bleb

分次皮内注射灭活脊髓灰质炎疫苗的免疫原性与皮内液泡的大小有关。

Bibby, Jack; Saidu, Yauba; Umesi, Ama; Moneke-Anyanwoke, Ngozi; Bashorun, Adedapo O; Hydara, Mariama Badjie; Adigweme, Ikechukwu; Adetifa, Jane U; Okoye, Michael; Roberts, Elishia; Clemens, Ralf; Bandyopadhyay, Ananda S; Muhammad, Abdul K; Mulwa, Sarah; Royals, Michael; Jarrahian, Courtney; Jeffries, David; Kampmann, Beate; Clarke, Ed

Antiviral Biologic Produced in DNA Vaccine/Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposure.

在 DNA 疫苗/鹅平台上生产的抗病毒生物制剂,在暴露后给药可保护仓鼠免受汉坦病毒肺综合征的侵害

Haese Nicole, Brocato Rebecca L, Henderson Thomas, Nilles Matthew L, Kwilas Steve A, Josleyn Matthew D, Hammerbeck Christopher D, Schiltz James, Royals Michael, Ballantyne John, Hooper Jay W, Bradley David S

A hantavirus pulmonary syndrome (HPS) DNA vaccine delivered using a spring-powered jet injector elicits a potent neutralizing antibody response in rabbits and nonhuman primates.

使用弹簧动力喷射注射器递送的汉坦病毒肺综合征 (HPS) DNA 疫苗可在兔子和非人灵长类动物中引发强效的中和抗体反应

Kwilas Steve, Kishimori Jennifer M, Josleyn Matthew, Jerke Kurt, Ballantyne John, Royals Michael, Hooper Jay W

Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies

DNA疫苗对小马的免疫原性和临床保护作用

Ault, Alida; Zajac, Alyse M; Kong, Wing-Pui; Gorres, J Patrick; Royals, Michael; Wei, Chih-Jen; Bao, Saran; Yang, Zhi-yong; Reedy, Stephanie E; Sturgill, Tracy L; Page, Allen E; Donofrio-Newman, Jennifer; Adams, Amanda A; Balasuriya, Udeni B R; Horohov, David W; Chambers, Thomas M; Nabel, Gary J; Rao, Srinivas S